Learning path for patent examiners

Assessment of inventive step: chemical inventions: Advanced level

Version: July 2022
Introduction

This publication, “Assessment of inventive step: chemical inventions, Advanced level”, is part of the "Learning path for patent examiners” series edited and published by the European Patent Academy. The series is intended for patent examiners at national patent offices who are taking part in training organised by the European Patent Office (EPO). It is also freely available to the public for independent learning.

Topics covered include novelty, inventive step, clarity, unity of invention, sufficiency of disclosure, amendments and search. Also addressed are patenting issues specific to certain technical fields:

- patentability exceptions and exclusions in biotechnology
- assessment of novelty, inventive step, clarity, sufficiency of disclosure and unity of invention for chemical inventions
- the patentability of computer-implemented inventions, business methods, game rules, mathematics and its applications, presentations of information, graphical user interfaces and programs for computers
- claim formulation for computer-implemented inventions

Each publication focuses on one topic at entry, intermediate or advanced level. The explanations and examples are based on the European Patent Convention, the Guidelines for Examination in the EPO and selected decisions of the EPO’s boards of appeal. References are made to the Patent Cooperation Treaty and its Regulations whenever appropriate.

The series will be revised annually to ensure it remains up to date.

Disclaimer

This publication is for training and information purposes only. Although it has been prepared with great care, it cannot be guaranteed that the information it contains is accurate and up to date; nor is it meant to be a comprehensive study or a source of legal advice. The EPO is not liable for any losses, damages, costs, third-party liabilities or expenses arising from any error in data or other information provided in this publication.

The opinions expressed in this publication are not necessarily those of the EPO.

This publication may be used and reproduced for non-commercial purposes, provided that the EPO and the contributors are appropriately acknowledged. Reproduction for commercial purposes is not permitted.

All references to natural persons are to be understood as applying to all genders.
Contents

1. Learning objectives 4

2. Inventive step in biotechnology: expectation of success 4

3. "Try and see" situation 4

4. Inventive-step assessment of antibodies 5

5. Kits-of-parts with instructions on a data carrier 6

6. Beyond the course 7

Legal references

Art. 56 EPC 4
GL G-VII, 13 4
CL Book I.D.7.1 4
Art. 56 EPC 5
CL Book I.D.7.2 5
Art. 56 EPC 6
GL G-II, 5.6.2 6
Art. 56 EPC 6
GL G-VII 5.4; G-II 3.7.1 6
T 2948/18 6
1. **Learning objectives**

Participants to this course will learn:
- The definition and jurisprudence concerning "expectation of success" and the "try and see" situation when assessing inventive step.
- The requirements of Article 56 EPC with regards to antibody related inventions based on technical facts.
- The special case of the kits of parts with instructions on a data carrier.

2. **Inventive step in biotechnology: expectation of success**

Obviousness occurs not only for the solution of a technical problem but also when there is a reasonable expectation of success (T 149/93).

A solution is obvious if the person skilled in the art would have followed the teaching of the prior art with a reasonable expectation of success.

**Examples**

A claim to anastrozole for use in treating early-stage breast cancer was supported by comparative data showing anastrozole to be better than tamoxifen even in early-stage breast cancer:
- Two drugs (anastrozole and tamoxifen) were known as cancer medications.
- Tamoxifen was particularly known for treating early-stage breast cancer.
- Anastrozole was known to be superior to tamoxifen in advanced-stage breast cancer.
- Early-stage and advanced-stage breast cancer have different requirements in treatment ("different clinical situation").
- The claim was considered not inventive. Finding anastrozole to be better than tamoxifen in early-stage breast cancer was not predictable but the skilled person had a "reasonable expectation of success" because anastrozole was also better in advanced-stage breast cancer.
- T 1577/11 concluded that, given the superior efficacy of anastrozole over tamoxifen in treating advanced breast cancer, there was a reasonable expectation it would also improve the treatment of early breast cancer compared with tamoxifen.

**Legal references:**
- Art. 56 EPC
- GL G-VII.13
- CL Book I.D.7.1

3. **"Try and see" situation**

When the prior art suggests testing an approach and neither the implementation nor the testing of the approach involves any difficulties, then the skilled person may be said to simply apply a "try and see" attitude, which can be a reason for denying inventive step.

A "try and see" situation is considered to have occurred if the skilled person, in view of the teaching in the prior art, has already clearly envisaged a compound or group of compounds and then carried out routine tests to determine whether that compound/those compounds had the desired effect (T 889/02, T 542/03, T 1241/03, T 1599/06, T 1364/08).
In these situations, the concept of "reasonable expectation of success" does not apply.

Legal references:
Art. 56 EPC
CL Book I.D.7.2

4. Inventive-step assessment of antibodies

Antibody defined by antigen specificity:

"An antibody Y that binds to antigen X"
- In T.0582/95, the board ruled that if the antigen X was unknown and the antibodies against X were unknown, both novelty and inventive step could be acknowledged.
- The subject-matter of a claim defining a novel, further antibody binding to a known antigen does not involve an inventive step unless the application shows a surprising technical effect. Examples of surprising technical effects when compared with known and enabled antibodies are, for example, improved affinity, improved therapeutic activity, reduced toxicity or immunogenicity, unexpected species cross-reactivity or a new type of antibody format with proven binding activity.
- If the surprising technical effect involves binding affinity, the structural requirements for conventional antibodies inherently reflecting this affinity must comprise the six CDRs and the framework regions because the framework regions can also influence affinity.
- If inventive step relies on an improved property versus the enabled antibodies of the prior art, the main features of the method for determining the property must also be indicated in the claim or by reference to the description (Guidelines F-IV, 4.11.1).

Antibody defined by structural features:
- For example: "Monoclonal antibody binding to X comprising a heavy-chain variable domain of SEQ ID NO:1 and a light-chain variable domain of SEQ ID NO:2".
- If a novel antibody binds to the same antigen as known antibodies, inventive step is not acknowledged solely on the basis that the novel antibody is structurally different from the known antibodies. Applying techniques known in the art to arrive at alternative antibodies is considered to be obvious to the skilled person. The fact that the structure of the thus obtained alternative antibodies, i.e. their amino acid sequences, is not predictable is not a reason for considering these antibodies non-obvious (see T.605/14, point 24; T.187/04, point 11).
- Nevertheless, antibodies can be inventive if the application overcomes technical difficulties in producing or manufacturing the claimed antibodies.

Examples

When assessing inventive step for an antibody defined by functional features the following questions can be helpful:
- Was the function known/suggested as being desirable?
- Are there routine ways to generate or select antibodies having that function?
- Is the scale of improvement predictable?

If the answer to any of them is yes, inventive step cannot be acknowledged.
5. Kits-of-parts with instructions on a data carrier

The boards of appeal describe a "kit-of-parts" as the juxtaposition of separate but functionally interacting individual components.

If the instructions are on a data carrier, then inventive step has to be assessed against a prior-art document disclosing the combination of reagents and a data carrier with different instructions.

According to Guidelines G-VII, 5.4, when applying the problem-solution approach to "mixed-type" inventions, the features which contribute to the technical character of the invention are determined on the basis of the technical effects achieved in the context of the invention (see G-II, 3.1 to 3.7). The instructions (presentation of information) have to be assessed in accordance with G-II, 3.7 in the context of inventive step (mixed-type inventions) and cannot be disregarded altogether under Article 52(2)(d) EPC; see also T 2948/18.

Non-technical features may nevertheless contribute to the technical character of an invention if, in the context of the invention, they contribute to producing a technical effect serving a technical purpose (G-VII, 5.4, second paragraph).

Examples

**Claim 1:** A method for diagnosing disease X comprising measuring marker Y by adding reagent A and reagent B to a sample leading to a change in colour which indicates disease X.

**Claim 2:** A kit (for carrying out the method) comprising reagents A and B and instructions for carrying out the method of claim 1 on a data carrier.

Claim 2 is distinguished from D1 on account of the instructions for carrying out the method of claim 1.

The instructions correspond to static or predetermined information about using the claimed reagents in the method as claimed, the effect of which is merely the non-technical effect of exempting the user from knowing or memorising how to carry out the method.

Claim 1 therefore lacks inventive step.

Legal references:

Art. 56 EPC
GL G-VII 5.4; G-II 3.7.1
T 2948/18
6. Beyond the course

You can deepen what you have learned during this course with the following further readings:
